EUCTR2004-000665-35-ES进行中（未招募）1 期
Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes - Not applicable
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women aged 18 to 75 years, documented metastatic breast disease, at least one bidimensionally measurable lesion adequately measured by imaging procedure, previously treated with anthracyclines and taxanes, Karnofsky performance status of 70 or greater, adequate haematological, hepatic and renal functions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Patient with poor prognosis disease, pregnant or lacting or of childbearing potential not using adequate contraception, malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade 2 or more dysphagia, other serious illness or medical conditions.
研究者
相似试验
进行中（未招募）
1 期
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer. - Not applicableEUCTR2004-000748-26-ESPierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament55
进行中（未招募）
1 期
Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer. - Not applicableTreatment in women with previously untreated HER2 negative metastatic breast cancer.EUCTR2004-000753-30-ESPierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament55
进行中（未招募）
1 期
A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclinesEUCTR2004-000963-81-BEPierre Fabre Medicament230
进行中（未招募）
不适用
A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclinesEUCTR2004-000963-81-ATRobapharm AG230
进行中（未招募）
1 期
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 12.1Level: LLTClassification code 10027475Term: <Manually entered code. Term in E.1.1>EUCTR2009-014497-18-FRPIERRE FABRE MEDICAMENT66